Nippon Shinyaku
 Nippon Shinyaku Head Office Exterior - Nishioji Street | |
| Type | Public (K.K)[1][2] |
|---|---|
| Industry | Pharmaceuticals, Functional Foods[1][2][3] |
| Founded | October 1, 1919 in Kyoto, Japan[2] |
| Headquarters | , |
Area served | Worldwide[1][2][3] |
Key people | Toru Nakai (President), Shigenobu Maekawa (Chairman), Takashi Takaya (Director), Kazuchika Takagaki (Director, Head R&D) |
| Products | Prescription drugs, functional foods[1][2] |
Number of employees | 2,243[2][4][5] (2025[2][5]) |
| Website | www |
Nippon Shinyaku Co., Ltd. is a Japanese pharmaceutical company headquartered in Kyoto that markets prescription drugs and functional foods.[6] Nippon Shinyaku has developed treatments such as viltolarsen for Duchenne muscular dystrophy.[7]
References
- 1 2 3 4 5 6 7 "Nippon Shinyaku Co Ltd (NPPNY) Company Profile". Stock Analysis. Retrieved 13 September 2025.
- 1 2 3 4 5 6 7 8 9 10 "Company Profile". Nippon Shinyaku. Retrieved 13 September 2025.
- 1 2 "Nippon Shinyaku Co., Ltd. Company Profile". MarketScreener. Retrieved 13 September 2025.
- 1 2 3 "Nippon Shinyaku Co Ltd Company Profile". Financial Times. Retrieved 13 September 2025.
- 1 2 "Nippon Shinyaku Co Ltd (4516.T) Employees". Stock Analysis. Retrieved 13 September 2025.
- ↑ Yamaura T (March 2011). "[History of the Nippon Shinyaku Institute for Botanical Research]". Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan (in Japanese). 131 (3): 395–400. doi:10.1248/yakushi.131.395. PMID 21372535.
- ↑ Dhillon S (July 2020). "Viltolarsen: First Approval". Drugs. 80 (10): 1027–1031. doi:10.1007/s40265-020-01339-3. PMID 32519222.